Chemical compounds studied in this article: DETQ (PubChem CID 117720272.) L-DOPA (PubChem CID 6407) SCH39166 (PubChem CID 107930) SKF 82958 (PubChem CID 1255) Keywords: D1 receptor Dopamine Eye-blink Positive allosteric modulator Potentiator Parkinson's disease a b s t r a c t DETQ, an allosteric potentiator of the dopamine D1 receptor, was tested in therapeutic models that were known to respond to D1 agonists. Because of a species difference in affinity for DETQ, all rodent experiments used transgenic mice expressing the human D1 receptor (hD1 mice). When given alone, DETQ reversed the locomotor depression caused by a low dose of reserpine. DETQ also acted synergistically with L-DOPA to reverse the strong hypokinesia seen with a higher dose of reserpine. These results indicate potential as both monotherapy and adjunct treatment in Parkinson's disease. DETQ markedly increased release of both acetylcholine and histamine in the prefrontal cortex, and increased levels of histamine metabolites in the striatum. In the hippocampus, the combination of DETQ and the cholinesterase inhibitor rivastigmine increased ACh to a greater degree than either agent alone. DETQ also increased phosphorylation of the AMPA receptor (GluR1) and the transcription factor CREB in the striatum, consistent with enhanced synaptic plasticity. In the Y-maze, DETQ increased arm entries but (unlike a D1 agonist) did not reduce spontaneous alternation between arms at high doses. DETQ enhanced wakefulness in EEG studies in hD1 mice and decreased immobility in the forced-swim test, a model for antidepressant-like activity. In rhesus monkeys, DETQ increased spontaneous eye-blink rate, a measure that is known to be depressed in Parkinson's disease. Together, these results provide support for potential utility of D1 potentiators in the treatment of several neuropsychiatric disorders, including Parkinson's disease, Alzheimer's disease, cognitive impairment in schizophrenia, and major depressive disorder.
Introduction
Many currently-used drugs work directly or indirectly through dopamine receptors. These include dopamine agonists and the dopamine precursor L-DOPA for Parkinson's disease, dopamine releasers for attention deficit disorder and narcolepsy, dopamine reuptake inhibitors for depression, and dopamine D2 antagonists for schizophrenia and bipolar disorder (Iversen and Iversen, 2007) .
Of the five mammalian dopamine receptors (Beaulieu and Gainetdinov, 2011) , D1 and D5 are closely related to each other, forming a subgroup of dopamine receptors that couple positively to adenylate cyclase through the G-proteins G s and G olf (Zhuong et al., 2000) . D2, D3, and D4 form a second subgroup of receptors that couple negatively to adenylate cyclase via G i . D1 and D2 are expressed at >10-fold higher levels than the other three receptors and appear to have the most important functional roles. The D1 and D2 receptors both have roles in motor activity and reward, but the D1 receptor has a special role in maintaining higher cognitive functions, in particular working memory, attention, and executive functions (Goldman-Rakic et al., 2004; Arnsten, 2013) . Given the important role of the D1 receptor, it is not surprising that selective D1 agonists 1 are active in animal models that relate to several clinical applications, including Parkinson's disease, schizophrenia, major depressive disorder, Alzheimer's disease, attention deficit disorder, and narcolepsy. Despite the promise of these preclinical results, attempts to develop D1 agonists for clinical use have so far not been successful, giving impetus to the search for alternative approaches to augmenting D1 receptor activity. One such approach would be to identify an allosteric potentiator (also known as a positive allosteric modulator or PAM) of the dopamine D1 receptor. 2 By increasing the affinity of dopamine for the D1 receptor, a D1 potentiator should amplify the response to endogenous dopamine, increasing D1 tone when and where dopamine is released. This mode of activity is in contrast to a D1 agonist, which will activate all D1 receptors to which it has access for as long as it is present. In animal models of cognition and locomotor activity, D1 agonists show bell-shaped dose-response relationships, which are probably due to overstimulation at higher doses (Zahrt et al., 1997; Arnsten et al., 2017) . Some D1 agonists also show rapid development of tolerance due to constant activation of the D1 receptor (Gulwadi et al., 2001) . In contrast, because a D1 potentiator would be dependent on endogenous tone and thus subject to normal feedback control, it should have a much lower propensity for overstimulation. Furthermore, since physiological tone is intermittent (Paladini and Roeper, 2014) , there should be less potential for tolerance development. These predictions were recently verified experimentally (Svensson et al., 2017) . Our efforts in this direction led to the discovery of DETQ, a novel allosteric potentiator of the dopamine D1 receptor (Beadle et al., 2014; Svensson et al., 2017) . DETQ causes a large (21-fold) leftward shift in the concentration-response curve for dopamine with a K b of 26 nM. In functional assays, it shows greater than 1000-fold selectivity for the D1 receptor over closely related receptors such as D5, D2, b 1 , b 2 , b 3 , and 5-HT6. Due to lower affinity of DETQ for rodent D1 receptors compared to the human D1, DETQ showed little in vivo activity in wild-type rats and mice. To enable use of DETQ and its congeners in rodent models, a line of transgenic mice in which both copies of the murine D1 receptor were replaced with its human counterpart (hD1 mice) was created. Although D1 receptor density in hD1 mice is about half that of wild-type controls, behavior of the animals appears normal, and habituated hD1 mice show a~10-fold maximal increase in LMA in response to DETQ (Svensson et al., 2017) .
Unlike D1 agonists, D1 potentiators should require endogenous dopamine release for in vivo activity. The therapeutic utility of D1 potentiators will therefore be critically dependent on the presence of sufficient D1 tone in the relevant neuronal circuits. To explore this issue and provide guidance for future clinical studies of D1 potentiators, the current study surveys the activity of DETQ in a broad array of behavioral and neurochemical models that are known to respond to be D1 agonists, including models thought to be predictive of therapeutic utility in Parkinson's disease, Alzheimer's disease, schizophrenia, major depressive disorder, attention deficit disorder, and narcolepsy. In each of these models, DETQ shows activity qualitatively similar to D1 agonists, confirming the existence of sufficient endogenous dopaminergic tone to observe efficacy with a D1 potentiator mechanism. The results suggest multiple therapeutic opportunities for D1 potentiators.
Materials & methods

Materials
DETQ was synthesized as described (Beadle et al., 2014) . Dopamine agonists and antagonists and other drugs were purchased from Sigma-Aldrich (St. Louis, MO). Sources of other materials are given with the respective protocols (below). DETQ and L-DOPA were administered as the parent compound. Doses of carbidopa monohydrate, imipramine HCl, pargyline HCl, rivastigmine tartrate, SCH39166 HBr, and SKF 82958 HBr were based on the amount of parent compound. Doses were calculated based on amount of parent compound. For instance, 100 mg of a compound that is 60% parent counts as 60 mg of parent in calculating the dose.
Animals, housing and care
Transgenic mice in which the mouse D1 receptor was replaced with the human D1 were derived as described (Svensson et al., 2017) . The strain was maintained in the homozygous state. For experiments in Indianapolis, hD1 mice were bred at Taconic (Hudson, NY), while for experiments in the UK animals were bred at Charles River (Margate, UK). Animals were 8e28 weeks of age (see individual experimental protocols) except for the chronically instrumented mice used in the EEG study (27e52 weeks). Agematched wild-type C57Bl/6 NTac mice were also purchased from Taconic (US) or Charles River (UK). Genotyping was routinely performed by the breeder. All animals were housed in groups of 8 mice per cage (shoebox size, 45 Â 25 Â 20 cm with wood chip bedding) on a 12 h light/dark cycle with free access to standard animal laboratory food and water. All experiments were performed during the light cycle of the day (6 a.m.e6 p.m.). Except when otherwise indicated, mice were dosed p.o with oral gavage using a dose volume of 10 ml/kg. All experimental procedures were pre-approved by the local animal care and use ethical committee according to NIH guidelines and the Declaration of Helsinki. In the UK all procedures were carried out in accordance with the UK Animals Scientific Procedures Act (1986) and associated guidelines, the European Communities Council Directive of 24 November 1986 (86/609/EEC) and passed the Lilly UK ethical review. The Eli Lilly and Company animal care and use program is fully accredited by AAALAC.
All monkey housing in the Shanghai ChemPartner large animal facility is fully accredited by AAALAC. Monkeys were socially pairhoused in two interconnected cages, enabling visual and verbal communication with neighboring monkeys as well as self-viewing from a hanging mirror on each cage. The cage dimension for each monkey was 0.9 (L) X 0.9 (W) X 2 (H) m, with gourd, foraging ball, or ball chew provided inside. The enrichment program included television shows 2e3 times per week and background music for several hours every other day. Animal health status was checked periodically by the attending veterinarian and daily by the animal care staff, including 1) appearance, hair, tail; 2) feces and urination; 3) gross behavior, food consumption and signs of illness. 
Measurement of locomotor activity (LMA) in reserpinized hD1 mice
This set of experiments was carried out in non-habituated mice. Male hD1 mice (8e10 weeks old) were dosed with reserpine at 0.3 or 2.5 mg/kg, s.c. (dissolved in 80% DMSO þ water) 18e20 h prior to the experiment and replaced in their home cages. The next day the mice were dosed with test compounds: DETQ was dosed p.o. 15 min before animals were placed in the LMA cage. Carbidopa and L-DOPA were dosed together i.p. 30 min before animals were placed in the LMA cage. Locomotor activity was recorded for 60 min beginning as soon as the animals were placed in the LMA cage. DETQ was dissolved in 20% 2-hydroxypropyl-b-cyclodextrin, and carbidopa/L-DOPA were dissolved together in water with small additions of HCl. All injections were made using a 10 ml/kg body weight dose volume.
Monitoring of mouse LMA took place in transparent plastic shoebox cages having dimensions of 45 Â 25 Â 20 cm, with a 1 cm depth of wood chips for absorbent bedding, and covered with a ventilated filtered plastic cage top. Cages were placed in a rectangular frame containing a grid of 12 photocell beams in an 8 Â 4 configuration (Kinder Scientific, Poway, CA) that was positioned 2.5 cm from the floor of the cage for the detection of body movements (ambulations) and recorded by computer for analysis.
After the activity sessions, reduced data using Hamilton Kinder software was used for statistical calculations. Calculation of data based on total ambulations was done using Microsoft Excel. Graphing and statistical analysis of data was done in GraphPad Prism (La Jolla, CA) as described in figure legends.
Microdialysis
Male hD1 mice (approximately 16e28 weeks old) were anesthetized with Isoflurane ® (2.5% in O 2 at 1 l/min) and administered the sedative and analgesic Domitor ® (1 mg/kg; 0.1 mg/ml medetomidine HCl; 10 ml/kg s.c.), before being positioned on the stereotaxic frame. Surgical anesthesia was then maintained at 1e1.5% Isoflurane ® in O 2 at 0.5 l/min, and body temperature was maintained at 36e37 C using a heated pad. MAB 4 microdialysis probes (4.7.2 Cu 6 kDa cut-off; RoYem Scientific Ltd, Bedford, UK) were implanted stereotaxically into the medial prefrontal cortex of each mouse while being perfused with artificial cerebrospinal fluid (141 mM NaCl, 5 mM KCl, 0.8 mM MgCl 2 and 1.5 mM CaCl 2 ) using coordinates from bregma and dura surface (with bregma and lambda in the same horizontal plane and probe angled at 9 ):
Probes were fixed in place with two skull screws and dental cement. Atipam ® (5 mg/kg; 0.5 mg/ml altipamezole HCl; 10 ml/kg, s.c.) and Rimadyl ® (5 mg/kg; 0.5 carprofen; 10 ml/kg, s.c.) were administered post-surgery as an anti-sedative and painkiller, respectively. Animals were allowed to recover in a thermacage (28e30 C) before being returned to their individual home cage. The day following probe implantation, animals were connected to a liquid swivel suspended on a counterbalanced arm, allowing the probes to be perfused with artificial cerebrospinal fluid via an infusion pump at 1.5 ml/min. Following a 90-minute pre-sample washout period, dialysate samples were collected at 20-minute intervals. After six baseline samples (120 min) animals were injected orally with either DETQ or vehicle (20% 2-hydroxypropryl b-cyclodextrin; 10 ml/kg). Samples were collected for 3 h post drug administration. All samples were immediately frozen on dry ice and stored at À80 C pending analysis.
For analysis, to each dialysis sample (29 ml) was added: 20 ml buffer (1 M Bis-Tris, pH 10), 20 ml mixed deuterated standard, and 260 ml 0.1% w/v dansyl chloride (in acetone). The samples were vortexed and heated at 65 C for 30 min, then dried under N 2 and re-suspended in 40 ml 50:50 (v/v) acetonitrile/:water (containing 10 mM ammonium formate and 0.06% formic acid). The samples were then centrifuged at 13,000 rpm for 10 min at ambient temperature and 35 ml pipetted into 03-FIVR vials; 10 ml was injected onto the LC-MS/MS using a CTC PAL HTC-xt Autosampler (Zwingen, Switzerland).
Chromatographic separation of dansylated samples (including DETQ standards) was performed under a 13-minute gradient (including washout and a re-equilibration step) using Shimadzu LC-20AD XR binary pumps (plus a CBM-20 controller) (Kyoto, Japan) and a 2.6 mm Phenomenex Kinetex, XB-C18 HPLC column (Macclesfield, UK). Mobile phase A consisted of acetonitrile/water 5:95 (v/v), 2 mM ammonium formate and 0.06% formic acid, and mobile phase B, acetonitrile/water 95: 5 (v/v), 2 mM ammonium formate, and 0.06% formic acid.
An AB Sciex API5500 (Framingham, MA) was operated in two periods: period 1 with positive TIS mode for detection of acetylcholine, and period 2 with positive and negative TIS modes (negative for glycine, glutamate, and glutamine). A 20 ms dwell time was used on the majority of analytes with MS conditions optimized individually by infusion of the dansylated derivative.
Data was expressed as a percentage of a pre-injection control period obtained by averaging the three samples prior to drug delivery (¼100%) and expressing values as a percentage of this value. The amount of analyte in each microdialysate sample was recorded as a peak area or height. Calibration curves allowed calculation of the amount (ng/ml) of DETQ in each dialysate fraction. Statistical analyses were undertaken using RM/Fit for comparing responses over time following drug or vehicle treatment (ANOVA with repeated measures).
Measurement of histamine metabolites and cyclic nucleotides in striatum
For measurement of histamine metabolites, male C57Bl/6 and hD1 mice were obtained from Taconic at 8e10 weeks of age and were acclimated for at least one week prior to testing. Mice were treated with vehicle (20% 2-hydroxypropyl-b-cyclodextrin, Sigma) or DETQ p.o. using a 10 ml/kg dose volume for 4 h, then sacrificed by decapitation and the striatum dissected. The MAO inhibitor, pargyline hydrochloride (Sigma), used as a positive control for histamine metabolites, was prepared in 0.9% saline and dosed at 75 mg/kg, i.p., 3 h prior to sacrifice. Dissected tissues were removed and placed immediately on a metal sheet over dry ice.
For measurement of cyclic nucleotides, hD1 mice 10e12 weeks old, weighing between 20 and 30 g, were dosed with vehicle (20% 2-hydroxypropyl-b-cyclodextrin) or DETQ at 30 mg/kg i.p., 1 h prior to sacrifice using a 10 ml/kg dose volume. [Intraperitoneal dosing was used to avoid stress associated with oral gavage.] The mice were sacrificed using focused-beam microwave fixation (Thermax Thermatron, Louisville, KY) at setting 0.6 s at high power. Striatum was removed and placed immediately on a metal sheet over dry ice.
For LC-MS/MS analysis, tissue weights were recorded and brain samples processed using probe sonication in acetonitrile/0.1% formic acid added at 4 times tissue weight. Processed samples were centrifuged at 13,000 RPM for 15 min at 4 C. Samples were analyzed for the histamine metabolites tele-methylhistamine (tMH) and tele-methylimidazoleacetic acid (tMIAA) and the cyclic nucleotides cAMP and cGMP using Agilent Technologies Inc. LC-MS/MS (Santa Clara, CA, USA). The calibration standards tMH, tMIAA, cAMP, and cGMP were purchased from Sigma. Stocks were made at 1 pg/ml in acetonitrile/1% FA and kept at 4 C. The analysis of standards was carried out using an Agilent 6410 series triple quad LC-MS/MS with MassHunter data analysis software fitted with an electrospray ion source and run in positive mode. The chromatographic separation employed an Agilent Zorbax RX-SIL Narrow-Bore 2.1 Â 150 mM 5-Micron Column. The mobile phase consisted of 3% acetonitrile in water with an overall 0.1% formic acid content. Clearly delineated chromatographic peaks with the retention time of authentic standards and expected molecular weight were seen after each injection of sample.
Mean results from the LC-MS/MS were calculated as ng/g using Excel and data expressed as either percent vehicle control or ng/g levels. GraphPad Prism was used to calculate statistical significance using one-way ANOVA and unpaired t-test versus vehicle. Data exclusions were detected using the Grubb's test for outliers (also known as the extreme studentized deviate [ESD] test).
Measurement of CREB and AMPA receptor phosphorylation
Transgenic hD1 mice were mock-dosed and handled for 3 days before the experiment day. On the day of the experiment, mice (male 8e10 weeks old) were weighed and subdivided into treatment groups. DETQ was given p.o. and SKF 82958 and SCH39166 were given s.c. All doses were given in a volume of 10 ml/kg. When used, SCH39166 was dosed 5 min before DETQ. Thirty min after dosing with DETQ or SKF 82958, mice were sacrificed by focused microwave irradiation (4 kW for 0.55 s) using a small animal microwave (microwave fixation system model GA5031; Gerling Applied Engineering, Modesto, CA). Mouse brains were rapidly removed and dissected after microwave fixation. Striata were snap frozen by liquid N 2 and stored at À80 C. Frozen tissue samples were sonicated in TBS/SDS lysis buffer [50 mM Tris-HCl, pH 7.5; 150 mM NaCl; 2 mM EDTA; 2% SDS; PhosSTOP tablet (ThermoScientific, Waltham, MA); COMPLETE protease inhibitor tablet (Roche Diagnostics, Indianapolis, IN)]. Small aliquots of the homogenate were used for protein determination by the BCA protein assay method (Pierce 23225, Thermo Scientific) using bovine serum albumin as a standard.
Equal amounts of protein (35e45 mg) were loaded onto 4e20%
Criterion TGX 26-well Tris-glycine SDS-PAGE gels (BioRad #567-1095, Hercules, CA) along with pre-stained dual color Precision Protein Standards (BioRad #161-0342). Proteins were resolved by electrophoresis in 1X Tris-glycine-SDS running buffer, and transferred to BioRad nitrocellulose membranes (BioRad #162-0235, 0.45 mm).
Membranes were blocked for 60 min in TBST (TBS, BioRad #170-6435 -20 mM Tris, 500 mM NaCl, pH 7.5, with 0.1% Tween-20 (Sigma)) containing 5% nonfat dry milk. The membranes were divided into upper and lower halves. The upper half of the membranes was immunoblotted using either a rabbit monoclonal antibody, clone D10G5 (1:1000, Cell Signaling #8084, Danvers, MA), that selectively detects the Ser-845 phosphorylated form of GluR1 or rabbit polyclonal antibody against total GluR1 (1:1000, Millipore #AB1504, Waltham, MA), while the lower half of each membrane was immunoblotted using either a rabbit monoclonal antibody, clone 87G3 (1:1000, Cell Signaling #9198), that selectively detects the Ser-133 phosphorylated form of CREB or a rabbit monoclonal antibody, clone 4GH2 (1:1000, Cell Signaling #9197), to detect total CREB. Antibody binding was revealed by horseradish peroxidaselinked mouse or rabbit secondary antibody (Cell Signaling, 1:20,000) and the ECL immunoblotting detection system (Pierce West Femto).
Signals were quantified via analysis of scanned images by Kodak/Carestream MI v5.2.2 software and Ser-133 phosphorylated CREB (pCREB) and Ser-845 phosphorylated GluR1 (pGluR1) net intensities were normalized to total CREB (tCREB) and total GluR1 (tGluR1) densitometry signals respectively. Data were analyzed using GraphPad Prism employing ANOVA followed by Dunnett's multiple comparisons test (for dose-response experiments) or Sidak's multiple comparisons test (for antagonist experiments).
Arm entries and alternation in the Y-maze
Animals were housed in standard housing conditions (individually ventilated cage, 07.00 to 19.00 light phase), constant temperature (19e23 C) and humidity (50% ±10), ad lib food and water. Treatments were given at 10 ml/kg. Experiment 1: SKF 82958. Male and female hD1 mice about 20 weeks of age (34.5 g ± 0.56 g and 28.2 g ± 0.57 g respectively; Charles River, UK) were randomized to treatment groups and were each dosed via the subcutaneous route with drug (0.1, 1, 3 mg/kg SKF 82958) or vehicle (0.9% saline) 30 min prior to placement in a Y-shaped arena for 15 min.
Experiment 2: DETQ. Male hD1 mice about 15 weeks of age (30.9 g ± 0.24 g; Charles River, UK) were assigned to treatment groups via a random number generator and were each dosed via the oral route with drug (3, 10, 30, 60 mg/kg DETQ) or vehicle (20% 2-hydroxypropyl-b-cyclodextrin) 60 min prior to placement in a Yshaped arena for 15 min.
Activity was measured in a controlled lighting environment in 4 clear Perspex Y-shaped arenas placed on infrared fields monitored via overhead infrared cameras. The camera images were fed into a PC and analyzed with the image analysis application Ethovision (v8.5, Noldus, Leesburg, VA). The number of arm entries (defined as when the animal placed all 4 paws inside an arm of the Y-maze) and the number of alternations (defined as successive entries into each of the three arms based on overlapping triplet sets) were used to calculate the percent alternation measure: 100 Â [(number of alternations)/(number of arm entries e 2)]. The percent alternation and distance moved data were exported to MS Excel 2010 for processing and imported into STATISTICA (v12, Statsoft) for statistical analyses. No significant gender effect was found for experiment 1, so results for male and female animals were pooled in subsequent analyses. A general linear model approach was used for all multivariate ANOVAs calculated for the data. Following ANOVA, planned comparisons of least square means were used to investigate significant differences from the vehicle treated control animals.
EEG sleep/wake study
Male hD1 mice were used in this study. Each mouse (approximately 30e40 g at time of surgery) was anesthetized and surgically prepared with a cranial implant that permitted chronic electroencephalogram (EEG) and electromyogram (EMG) recording. As these mice were used chronically with appropriate wash-out periods in between studies, their ages ranged from about 27 to 52 weeks of age. The implant was placed so that the stainless steel screws were positioned at the following skull locations bilaterally: two frontal (2.0 mm anterior to bregma, and 2.0 mm lateral to the sagittal suture) and two occipital (3.0 mm posterior to bregma, and 3.0 mm lateral to the sagittal suture). Two Teflon-coated stainless steel wires were positioned under the trapezoid muscles for EMG recording. The implant assembly was affixed to the skull by the combination of the EEG recording screws, cyanoacrylate applied between the implant connector and skull, and dental acrylic. Body temperature and locomotor activity were monitored via a miniature transmitter (Minimitter type G2 E-Mitter, Bend, OR) surgically placed in the abdomen. Animals were administered appropriate analgesic and antibiotic treatment and allowed least 3 weeks for recovery.
Animals were housed individually within a specially modified Ancare™ microisolator cage (Bellmore, NY) with an ultra-low-torque slip-ring commutator (Hypnion, Inc.). A custom engineered flexible tether connected at one end to the commutator and at the other end to the animal's cranial implant. Each cage was located within separate, ventilated compartments of a stainless steel sleepwake recording chamber, with an infrared light source and digital video camera to allow a minimum of twice daily remote visual monitoring. Food and water were available ad libitum and the ambient temperature was 21 ± 2 C. A 24-hour light-dark cycle (LD 12:12) using white LEDs was maintained and monitored throughout the study. Light intensity averaged 35e40 lux at mid-level inside the cage. Relative humidity averaged 50% approximately. Animals were undisturbed for 48 h before and after each drug treatment.
Animals received vehicle (20% 2-hydroxypropyl-b-cyclodextrin), 10, 30 or 60 mg/kg of DETQ dosed orally, or 0.3 mg/kg SKF 82958 or 0.1 mg/kg SCH39166 dosed s.c. with s.c. vehicle (1% hydroxyethylcellulose). Sleep and wakefulness were determined using SCORE-2004™ d a microcomputer-based sleep-wake and physiological monitoring system. Validation of the SCORE™ technology in rodents and its utility in pre-clinical drug evaluation have been previously described (Seidel et al., 1995) . In the present study, the system monitored amplified EEG (X10,000, bandpass 1e30 Hz [Grass Corp., Quincy, MA]; initial digitization rate 400 Hz), integrated EMG (bandpass 10e100 Hz, RMS integration), and telemetered body temperature and non-specific locomotor activity. Arousal states were classified on-line as NREM sleep, REM sleep, wake, or theta-dominated wake every 10 s using EEG period and amplitude feature extraction and ranked membership algorithms. Individually taught EEG-arousal-state templates and EMG criteria differentiated states of arousal.
Forced-swim test
Male hD1 mice (8e10 weeks of age) were placed in clear, plastic cylinders (diameter: 10 cm; height: 25 cm) filled to 6 cm with 22e25 C water for 6 min. The duration of immobility was recorded during the last 4 min of a 6-minute trial. A mouse was regarded as immobile when floating motionless or making only those movements necessary to keep its head above the water. The amount of time spent immobile was analyzed by post-hoc Dunnett's test. DETQ was suspended in 20% 2-hydroxypropyl-b-cyclodextrin and dosed p.o. 30 min prior to testing. Imipramine (Sigma) was given at 15 mg/kg, i.p. 30 min prior to testing as a positive control. All compounds were dosed at 10 ml/kg dose volume.
2.10. Monkey eye-blink 2.10.1. Subjects
The study used 14 male 5e6 year old rhesus monkeys (Chengdu Ping An Animal Breeding and Research Base, SiChuan Province), average weight 5.2 kg.
The monkeys were housed individually in a climate-controlled and humidity-controlled vivarium. Monkeys had unlimited access to water and received a daily allotment of high-protein monkey chow, supplemented with fresh fruit every day. On the day of testing, animals were not fed until testing was completed.
Apparatus and experimental methods
Eye-blink experiments were conducted in a specially constructed monkey chair. A neck plate that fixed the orientation of the head was used to facilitate observation of eye-blink response. A compact video camera (Panasonic/wv-cp480/CH) mounted on a tripod was positioned in front of two seated monkeys. Two camera images were combined by video collector (Color QUAD system) and transferred to the EthoVision software in the computer for viewing and recording.
Two weeks before test, subjects were trained to sit in the monkey chair. During test sessions, each monkey was studied for nine consecutive 15-min components. Each 15-min block consisted of a 10-min habituation period followed by a 5-min period during which eye blinking was counted. The video camera displayed the image on a computer screen to allow continual observation of the subject. Observers blind to the treatment conditions later scored the 5-min videotaped session. An eye-blink was defined as a visible, rapid opening and closing of the eyelid. Each measurement was carried out by two observers with reliability >90%.
Drug testing
Compound or vehicle was dosed after two baseline eye-blink recordings. Cumulative dosing was studied in four or five subjects; drug or vehicle was given in random order to different monkeys. The injection volume for DETQ was 5 ml/kg (i.m.) in 1% hydroxyethylcellulose. SKF 82958 was dosed s.c. using saline as vehicle.
Data analysis
Results for each monkey were expressed as the rate of eye blinking (blinks per minute) averaged over each 5-min testing epoch. The effects of vehicle and drug on eye blinking were averaged for each group of monkeys and expressed as mean ± SE. The effects of drug and vehicle were analyzed with two-way ANOVA (drug and time) followed by Bonferroni post-hoc test (GraphPad Prism).
Results
Reversal by DETQ of the decrease in LMA caused by a low dose of reserpine
As a potential model of mild-to-moderate Parkinson's disease, non-habituated hD1 mice were pretreated with a low dose of reserpine (0.3 mg/kg s.c.) that caused a 70% decrease in LMA (Fig. 1) . Fig. 1 . Effect of DETQ (10 and 30 mg/kg p.o.) on LMA in non-habituated hD1 mice pretreated with a low dose of reserpine (0.3 mg/kg s.c.). Bars represent means ± SE of 8 mice. Data were analyzed by a one-way ANOVA (p < 0.0001) followed by unpaired ttest comparing vehicle/vehicle with reserpine/vehicle (****p < 0.0001) and reserpine/ vehicle with reserpine/DETQ (#p < 0.05, ####p < 0.0001). Striatal dopamine levels measured by LC/MS were 31.6 ± 2.2 nmol/g in control mice and 21.5 ± 2.1 nmol/g in hD1 mice treated with 0.3 mg/kg reserpine (68% of control, p < 0.01, Student's t-test, n ¼ 6).
LMA was partially restored by a lower dose of DETQ (10 mg/kg) and completely restored by a higher dose (30 mg/kg).
3.2.
Interactions between DETQ and a low dose of L-DOPA in mice pretreated with a high dose of reserpine As a potential model for severe Parkinson's disease, nonhabituated hD1 mice were pretreated with a higher dose of reserpine (2.5 mg/kg, s.c.), which decreased LMA by about 99.8% (3.5 ± 1.0 ambulations, compared to~2500 ambulations seen historically in the absence of reserpine pretreatment) (Fig. 2) . Although DETQ at 10 and 30 mg/kg p.o. gave only very small increases in LMA, to 15 ± 4 and 34 ± 7 ambulations respectively, both responses nevertheless differed significantly from control (see Fig. 2 legend) . However, the response to 30 mg/kg DETQ was still only about 1% of the~4000 ambulations seen historically with this dose of DETQ in hD1 mice that were not pretreated with reserpine (Svensson et al., 2017) .
As a model of combination therapy, DETQ was tested in the presence of three doses of L-DOPA (each dose combined with 100 mg/kg carbidopa). Each dose of L-DOPA elicited a small increase in LMA on its own, and there was a supra-additive interaction between DETQ and L-DOPA in each of the 6 combinations of the two agents (Fig. 2) .
3.3. Effect of DETQ on release of histamine, ACh, and tMH from prefrontal cortex D1 receptor agonists and dopamine releasing agents are known to increase release of neurotransmitters such as ACh and histamine in multiple brain areas, including prefrontal cortex and striatum (Damsma et al., 1990; Ishizuka et al., 2003) . Administration of DETQ at 30 mg/kg orally to hD1 mice produced a significant increase in extracellular levels of histamine and ACh as well as the histamine metabolite tele-methylhistamine (tMH) in the prefrontal cortex (Fig. 3) . Levels of DETQ measured in the dialysate peaked at 160 min; assuming 20% recovery, free DETQ levels exceeded its in vitro EC 50 of 5.8 nM (Svensson et al., 2017 ) from 140 to 260 min (corresponding to 10e130 min after DETQ administration). In a separate experiment, administration of a lower 10 mg/kg oral dose of DETQ failed to evoke significant changes versus vehicle controls (data not shown).
Effect of combination treatment with rivastigmine and DETQ on ACh release from the hippocampus
The acetylcholinesterase inhibitor rivastigmine, originally developed for symptomatic treatment of Alzheimer's disease, has also been approved for treatment of dementia in Parkinson's patients (Emre et al., 2004) . Degeneration of cholinergic neurons that provide input to the hippocampus is thought to contribute to deficits in memory consolidation in Alzheimer's disease (Coyle et al., 1983) . Rivastigmine (0.3 mg/kg p.o., roughly an ED50 dose) and DETQ (30 mg/kg p.o.) each increased ACh release in hippocampus in hD1 mice (Fig. 4) when given alone. In combination, the increase in ACh was significantly higher than with either agent given separately. Statistical tests for synergism versus additivity were inconclusive: for the 160-min point, the 95% confidence interval for the difference between the combination and the sum of the two separate responses did not include zero (consistent with synergism), but all subsequent points included zero within the 95% confidence interval. No significant pharmacokinetic interactions between the two agents were seen (see Fig. 4 legend) .
Effect of DETQ on histamine metabolites and cyclic nucleotides in striatum of wild-type and hD1 mice
Accumulation of the histamine metabolites tMH and telemethylimidazoleacetic acid (tMIAA) is considered an index of histamine release (Fell et al., 2011) . Levels of tMH and tMIAA were measured in striata from wild-type and hD1 mice. The MAO inhibitor pargyline, which prevents metabolism of tMH to tMIAA, was used as a positive control. Two hours after treatment with DETQ, tMH and tMIAA exhibited dose-related increases in hD1 mice but not in wild-type mice (Fig. 5) . As expected, pargyline increased levels of tMH but decreased levels of tMIAA.
Although the D1 receptor is linked to stimulation of adenylate cyclase, D1 agonists also increase cGMP in the brain (Altar et al., 1990; Torremans et al., 2010) . The highest dose of DETQ (30 mg/ kg i.p.) increased striatal cAMP by 39% and cGMP by 53% compared to vehicle controls (Fig. 6 ).
Effect of DETQ on phosphorylation of CREB and AMPA receptor (GluR1) in striatum
By increasing cAMP, D1 receptor activation leads to activation of protein kinase A, which then phosphorylates various substrates, including cyclic AMP response element binding protein (CREB) at Ser-133 and the GluR1 subunit of the AMPA receptor at Ser-845 (Das et al., 1997; Snyder et al., 2000) . To assess the effect of DETQ Due to the high skew of the data distributions for vehicle and several other groups, the Mann-Whitney U test was used for all computations of statistical significance. All treatment groups were significantly different from vehicle: p < 0.05 for 10 mg/ kg DETQ vs vehicle; p < 0.0001 for all other comparisons with vehicle. All L-DOPA/ DETQ combinations were significantly different from either component tested alone (p 0.001). For each of the six combinations, the increase in ambulations minus the sum of the separate increases from L-DOPA and DETQ was greater than zero by at least twice the standard error of the difference. Striatal dopamine levels measured by LC/MS in a separate experiment were 45.9 ± 6.4 nmol/g in control mice and 2.3 ± 0.7 nmol/g in hD1 mice treated with 2.5 mg/kg reserpine (5% of control, p < 0.01, Student's t-test, n ¼ 3e4). DETQ did not have a significant effect on brain levels of L-DOPA nor did L-DOPA affect brain levels of DETQ (results not shown).
on D1-induced signaling, hD1 mice were administered DETQ or the D1 agonist SKF 82958, then euthanized after 30 min using a focused beam of microwave radiation followed by brain harvest and striatum dissection. Striatal homogenate was then subjected to analysis by western blot for measurement of phosphorylation of CREB and GluR1, with results for each being expressed as phosphorylated CREB or GluR1 divided by total CREB or GluR1 (Fig. 7) . Both SKF 82958 and DETQ dose-dependently increased CREB Ser-133 and GluR1 Ser-845 phosphorylation. The effects of DETQ were blocked by the D1 antagonist SCH39166 (Fig. 7) .
Comparison of the effects of DETQ and D1 agonist on spontaneous alternation
The spontaneous movement of naïve mice exploring a Y-shaped arena comprising 3 equidistant connected arms (Y-maze) is considered a correlate of spatial working memory (Montgomery, 1952) . The number of arm entries is related to general locomotor activity, whereas the percent alternation (entering a different arm than the one most recently visited) is related to efficiency of exploration, which depends on working memory. In this model, amphetamine has been shown to increase arm entries (indicative of locomotor stimulation) but decrease percent alternation (indicative of impaired spatial working memory) (Anisman and Kokkinidis, 1975 ). In the current study, the D1 agonist SKF 82958 Fig. 3 . Increase in release of histamine, ACh, and tMH from the prefrontal cortex in hD1 mice treated with DETQ (30 mg/kg p.o.). Animals were dosed shortly after the 120-min mark (arrow). In addition to biogenic amines and metabolites, levels of DETQ were measured in the dialysate. It should be noted that DETQ levels do not account for recovery, which was typically about 20% for this type of probe. Values are means ± SE, n ¼ 8. Data were analyzed by ANOVA with repeated measures: histamine, 140e240 min, p < 0.001; ACh, 140e240 min, p < 0.0001; tMH, 140e300 min, p < 0.001. Animals were dosed shortly after the 120-min mark (arrow). Values are means ± SE, n ¼ 7. Statistical comparisons were carried out on the 140e300 min time window using ANOVA (p < 0.001) with repeated measures. Significance comparisons: DETQ vs vehicle, p < 0.01; rivastigmine vs vehicle, p < 0.01; DETQ vs rivastigmine, N.S.; combination vs DETQ, p < 0.001; combination vs rivastigmine, p < 0.001. Rivastigmine and DETQ did not show any significant pharmacokinetic interactions by ANOVA as measured by AUC of dialysate levels uncorrected for recovery: DETQ control levels 3.6 ± 0.7 ng/ml vs 3.9 ± 0.6 with rivastigmine; rivastigmine control levels 0.38 ± 0.08 ng/ml vs 0.49 ± 0.09 with DETQ.
had little effect on arm entries but decreased percent alternation (Fig. 8) . In contrast, DETQ increased arm entries but did not affect alternation, a profile different from amphetamine (unpublished) or the D1 agonist.
Effect of DETQ on wakefulness in hD1 mice
Dopamine releasers such as amphetamines are used clinically to increase wakefulness, and D1 agonists have been shown to cause wakefulness in animals (Isaac and Berridge, 2003) . We therefore tested DETQ for effects on EEG in conscious freely moving hD1 mice. Initial studies demonstrated no difference in baseline sleep/ wake parameters between wild-type and hD1 mice. In a timecourse study (Fig. 9A ), animals were initially fully awake due to effects of handling and injection. Vehicle-treated hD1 mice returned to half-maximal sleep fraction at 42 ± 2 min, which was increased to 96 ± 1 min by 30 mg/kg DETQ and 146 ± 1 min by 0.3 mg/kg SKF 82958; conversely, the D1 antagonist SCH39166 shortened the sleep latency to 18.5 ± 0.5 min, in agreement with the sleep-inducing effects of D1 antagonism in humans (Eder et al., 2003) . Time awake during the first 7 h post-treatment increased with DETQ dose, but did not reach the same total duration as with 0.3 mg/kg SKF 82958 (Fig. 9B). 3.9. Activity of DETQ in the mouse forced-swim test D1 agonists are known to be active in the forced-swim test, a screen that has been historically used to identify compounds with antidepressant-like activity (Nikulina et al., 1991) . In hD1 mice, DETQ reduced immobility with an ED60 (dose reducing immobility to 60% of control) of 15.7 mg/kg p.o. and a maximal efficacy of 53%, comparable to that of 15 mg/kg imipramine (Fig. 10) . 5 . Effect of DETQ on tMH and tMIAA levels in striatum of wild-type and hD1 mice. The monoamine oxidase inhibitor pargyline was tested as a positive control. Striata were removed and assayed 2 h after vehicle or DETQ and 3 h after pargyline. Bars represent means ± SE of 6 mice. Data were analyzed by a 2-sided t-test: ****p < 0.0001 vs vehicle.
Monkey eye-blink
Non-rodent species such as dog and rhesus monkey have a high (human-like) affinity for DETQ (Svensson et al., 2017) . Parkinson's patients have a reduced spontaneous eye-blink rate (Karson et al., 1982; Deuschl and Goddemeier, 1998) and rhesus monkeys increase their eye-blink rate in response to D1 agonists (Jutkiewicz and Bergman, 2004) . The increased eye-blink caused by D1 agonists may therefore be a marker for counteracting the dopaminergic deficit in Parkinson's patients. DETQ and the D1 agonist SKF 82958 were tested for effects on eye-blink rate in rhesus monkeys using cumulative dosing. At 10 mg/kg (i.m.), DETQ caused an approximate doubling of eye-blink rate, while SKF 82958 increased eye-blink 7-fold (Fig. 11 ). Higher doses of DETQ could not be tested due to limited compound availability at the time that the experiments were carried out. However, in cynomolgus monkeys dosed with 10 mg/kg DETQ intramuscularly, free brain levels of DETQ calculated from free plasma levels and in vitro brain penetration exceeded the in vitro EC50 for the first six hr ( KA Svensson, unpublished results) , implying that this dose should have been adequate to elicit at least a half-maximum response. Results with other D1 potentiators from the same series (Beadle et al., 2014) also suggest that the maximum eye-blink response to D1 potentiators is slightly smaller than the response to SKF 82958 (L Zhang and CR Yang, unpublished results).
Discussion
A new approach for an old neurotransmitter
The neurotransmitter role of dopamine has been known for almost 60 years (Carlsson et al., 1958; Bjorklund and Dunnett, 2007; Iversen and Iversen, 2007) and numerous CNS drugs have been shown to work through dopaminergic mechanisms. These include L-DOPA and dopamine receptor agonists for Parkinson's disease, dopamine D2 receptor antagonists for schizophrenia, dopamine reuptake blockers for depression, and dopamine releasers for attention deficit hyperactivity disorder. Although each of these classes of drugs offers major therapeutic benefits, there are still areas of significant unmet medical need, especially with regard to treatment of the cognitive deficits that accompany these conditions. An abundant literature supports the role of cortical dopamine D1 receptors in higher cognitive functions (Goldman-Rakic et al., 2004) . However, efforts to develop orthosteric D1 receptor agonists have been hampered by tachyphylaxis and a narrow therapeutic window (Gulwadi et al., 2001; Arnsten et al., 2017 ). An allosteric potentiator of the dopamine D1 receptor represents an alternative approach that might avoid these disadvantages.
DETQ is the prototype of a class of selective and brain-penetrant D1 potentiators with a pharmacological profile clearly distinct from D1 agonists (Beadle et al., 2014; Svensson et al., 2017) . The actions of DETQ are dependent on endogenous dopaminergic tone, since the locomotor response to DETQ was essentially absent in animals in which dopamine was depleted by pretreatment with a high dose of reserpine (see Fig. 2 in the current study), was blocked by a D1 antagonist, and was absent in wild-type mice (which have low affinity for DETQ) (Svensson et al., 2017) . In contrast to D1 agonists, DETQ did not induce intense stereotyped behavior at high doses, exhibiting a monophasic rather than a "bell-shaped" dose response curve in locomotor activity. In addition there was no evidence of tachyphylaxis upon repeat dosing (Svensson et al., 2017) .
Central D1 pharmacology of DETQ
In the present study, we assessed the profile of DETQ in neurochemical and behavioral models reflective of potential therapeutic activity in neuropsychiatric disorders. These models were chosen based on known activity of D1 agonists and other dopaminergic agents.
The increase in cAMP caused by DETQ in HEK293 cells transfected with the human D1 receptor was dependent on the presence of dopamine (Svensson et al., 2017) . An important question is whether responses to DETQ in vivo are similarly dependent on D1 tone. Although DETQ did produce a statistically significant increase in LMA in animals depleted of dopamine by pretreatment with a high dose of reserpine, the increase in LMA at 30 mg/kg DETQ was only about 1% of the response seen in animals that were not pretreated with reserpine. This very small response could be due to a small amount of intrinsic activity of DETQ alone or to potentiation of a small residual amount of dopamine. Irrespective of these two possibilities, it is clear that virtually all of the LMA response to DETQ in vivo is dependent on dopaminergic tone.
Behaviorally, DETQ produced a dose-dependent activation in Ymaze locomotion, decreased immobility in the forced-swim test, Fig. 6 . Effect of DETQ on cAMP and cGMP in striatum of hD1 mice. DETQ was given i.p. Striata were removed and assayed 1 h after vehicle or DETQ. Bars represent means ± SE of 5e6 mice. Data were analyzed by a one-way ANOVA (p < 0.01 for cAMP, p < 0.0001 for cGMP) followed by Dunnett's multiple comparisons test: *p < 0.05, **p < 0.01 vs vehicle.
and increased wakefulness in sleep EEG. The D1/D5 agonist SKF 82958, used as a comparator in many of these experiments, gave results that were in good agreement with reports from the literature (Murray and Waddington, 1989; Nikulina et al., 1991; GeterDouglass et al., 1997; Isaac and Berridge, 2003) . Further behavioral evidence for DETQ-mediated central potentiation of D1 receptors was seen in its ability to increase spontaneous eye-blink rate in the rhesus monkey, as previously reported for D1 agonists (Jutkiewicz and Bergman, 2004) .
In neurochemical models, DETQ also displayed D1 receptormediated accumulation of cAMP and cGMP measured ex vivo. Similar effects have been reported with D1 but not D2 agonists (Altar et al., 1990) . DETQ also caused increases in cortical release of acetylcholine and histamine at a behaviorally activating dose. The positive connection between D1 receptor activation and both cortical and subcortical acetylcholine release is well documented (Damsma et al., 1990; Consolo et al., 1992; Day and Fibiger, 1993) . Contrary to reports that hippocampal ACh release induced by D1/ D5 agonists is exclusively mediated by the D5 receptor (Hersi et al., 2000; Laplante et al., 2004) , systemically administered DETQ Fig. 7 . Stimulation of the phosphorylation of CREB and the AMPA receptor (GluR1) by SKF 82958 and DETQ in striatum of hD1 mice and blockade of the DETQ response by SCH39166. DETQ was given p.o. and SKF 82958 and SCH39166 were given s.c.; brains were removed 30 min after dosing. Data were calculated as phosphorylated CREB or GluR1 as a fraction of total CREB or GluR1 and then normalized to vehicle. Bars represent means ± SE of 6 mice. Data were analyzed by a one-way ANOVA (p < 0.05 for effect of DETQ on CREB, p < 0.0001 for the other five comparisons) followed by Dunnett's or Sidak's multiple comparisons test: *p < 0.05, ***p < 0.001, ****p < 0.0001 vs vehicle; ###p < 0.001, ####p < 0.0001 for DETQ alone vs DETQ þ SCH39166.
robustly increased ACh release in hippocampus despite its complete lack of D5 activity (Svensson et al., 2017) , indicating that D1 receptor activation is sufficient to stimulate hippocampal ACh release in vivo. Compared to ACh release, the relationship of histamine release to D1 receptor activation is less explored. However, brain histamine release is known to be elicited by various forms of arousal, including stimulant drugs, handling-induced stress, and circadian changes in basal activity (Westerink et al., 2002; Horner et al., 2007; Fell et al., 2011) . Similar to SKF 82958 (Chartoff et al., 2006) , DETQ also showed dose-dependent increases in phosphorylation of the transcription factor CREB and the GluR1 subunit of the AMPA receptor in the striatum. The activity of DETQ in the above models implies that endogenous dopaminergic tone must be widespread in different brain areas Fig. 8 . Effects of SKF 82958 and DETQ on arm entries and alternation in the Y-maze in hD1 mice. Following multivariate ANOVA, planned comparisons were used to investigate significant differences from the vehicle-treated animals. A general linear model approach was used for all multivariate ANOVAs calculated for the data. Following ANOVA, a priori planned comparisons of least square means were used to investigate significant differences from the vehicle treated control animals. Bars represent means ± SE of 16 mice (DETQ) and 11e17 mice (SKF 82958). Statistical significances are denoted by the following symbols: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. , where m is the maximum response, k is sleep latency (time to return to half-maximal sleep rate), and s is the log 2 decay factor. Best-fit values ± SE for m, k, and s: vehicle, 70 ± 2%, 42 ± 2 min, 5.5 ± 1.2 min; SCH39166, 78 ± 1, 19.5 ± 0.5, 2.0 ± 0.3; DETQ 72 ± 1, 96 ± 1, 10.0 ± 0.8; SKF 82958, 69 ± 1, 146 ± 1, 7.7 ± 0.6. In B, analysis of covariance (ANCOVA) was used to estimate drug-effects using the equivalent baseline wake outcome value as a covariate. LS mean differences to vehicle for each treatment level were calculated for the 7 h in the light phase after treatment (CT5-12), *p < 0.05, ***p < 0.001 vs vehicle.
(striatum, PFC, and hippocampus) and across different behavioral and neurochemical domains. Relative to SKF 82958, the maximum response to DETQ was higher in Y-maze distance travelled, lower in CREB phosphorylation and monkey eye-blink, and roughly the same in GluR1 phosphorylation. The lower maximum response for SKF 82958 compared to DETQ in locomotor activity was previously shown to be due to induction of competing grooming behavior by SKF 82958, but not by DETQ (Svensson et al., 2017) . Conversely, the lower maximum response to DETQ in CREB and eye-blink could be due to lower available dopaminergic tone in these models or to other factors such as differences in pharmacokinetics between SKF 82958 and DETQ or the lack of D5 activity of DETQ.
Therapeutic opportunities for a selective D1 potentiator
Given the established role of central D1 receptors for critical functions such as higher cognitive functions, motor activity/arousal, mood, and reward, there are several therapeutic opportunities for a D1 potentiator.
Parkinson's disease
In hD1 mice that were partially depleted of dopamine by pretreatment with a low dose of reserpine, DETQ was able to restore LMA to the levels seen in control animals. This result suggests that D1 potentiators could show utility as monotherapy for motor symptoms in early Parkinson's patients with partial dopamine depletion, possibly delaying the need to initiate L-DOPA therapy. Additionally, the ability of DETQ to potentiate the effects of L-DOPA after a high dose of reserpine suggests an opportunity to lower the L-DOPA dose or improve the maximal effect of L-DOPA in patients with more severe dopamine deficiency. These results indicate potential beneficial effects of D1 potentiators on motor symptoms. The D1 receptor agonist ABT-431 has been tested clinically in Parkinson's disease and showed clear evidence of efficacy on motor symptoms; it showed a lower rate of dyskinesias compared to L-DOPA in one study but this advantage was not confirmed in a second study (Giardina and Williams, 2001 ). Given the difference in mechanism between the two types of agents (Svensson et al., 2017) , it is unclear whether the dyskinesia liability of D1 receptor agonists will also apply to D1 potentiators.
Parkinson's patients also suffer from non-motor symptoms, including cognitive impairment. The cognitive symptoms are heterogeneous and range from early prefrontal dysfunctions with executive, planning, and working memory deficits to later stage memory impairment and dementia. The pathology of cognitive impairment in Parkinson's disease likely involves prefrontal dopamine dysfunction as well as hypo-activity in cholinergic projections from the basal forebrain (Williams-Gray et al., 2006; Kehagia et al., 2013; Narayanan et al., 2013) . The only approved therapy is the acetylcholinesterase inhibitor rivastigmine, which is prescribed for moderate to severe dementia (Emre et al., 2004) but has a narrow therapeutic index (Winblad et al., 2007) . DETQ showed clear neurochemical evidence of forebrain activation, with significant increases in both acetylcholine and histamine release. The increased formation of cAMP and cGMP and activation of both CREB and GluR1, markers that are implicated in synaptic plasticity and memory function, also support the potential efficacy of D1 potentiators in neurocognitive disorders in Parkinson's disease (Sheng and Kim, 2002) . Given that Parkinson's patients show a reduced eye-blink rate (Karson et al., 1982) , the ability of DETQ to increase eye-blink rate in rhesus monkeys suggests potential efficacy against attentional deficits in Parkinson's disease (Jongkees and Colzato, 2016) . In addition, the observed effects of DETQ in the forced-swim and sleep EEG models support the concept that this mechanism could benefit other non-motor symptoms in Parkinson's disease such as depression, apathy/anhedonia, and excessive daytime sleepiness (Poewe, 2008) .
Alzheimer's disease
Based on the enhanced hippocampal ACh release with DETQ, it is possible that D1 potentiators could provide symptomatic Fig. 10 . Forced-swim test in hD1 mice. Imipramine (15 mg/kg i.p.) is included as a positive control. Bars represent means ± SE of 6e8 mice. Data were analyzed by ANOVA (overall significance p < 0.0001) followed by Dunnett's multiple comparisons test: *p < 0.05 vs vehicle. Fig. 11 . Effects of SKF 82958 and DETQ on monkey eye-blink. Rhesus monkeys were dosed i.m. at the times marked by arrows and eye-blink rate was measured for a 5-min period starting at the end of each 15-min recording block. Data points represent means ± SE of 5 (vehicle and DETQ) or 4 (SKF) animals. Statistical significance by one-sided t-test with Bonferroni correction: *p < 0.05, **p < 0.01, ****p < 0.0001 vs vehicle at the same time point. treatment of memory impairment also in Alzheimer's disease. The observed additive effect with rivastigmine is of particular interest regarding adjunctive therapy. Alzheimer's patients also suffer from non-cognitive, neuropsychiatric symptoms that contribute to patient disability and caregiver stress (Cummings et al., 1994) . It is possible that D1 potentiators could treat mood-related symptoms (apathy and loss of interest) and daytime sleepiness; smaller clinical studies with methylphenidate (Rosenberg et al., 2013 ) support a dopaminergic approach.
Schizophrenia
Schizophrenia is a complex psychiatric disorder in which the patients exhibit positive symptoms (hallucinations, delusions, and agitation), negative symptoms (anhedonia and social withdrawal), and cognitive impairment, particularly attentional, working memory, and executive functional deficits. Although positive symptoms respond well to current antipsychotic therapy, there is still a need for agents that more effectively treat negative and cognitive symptoms. While imaging studies suggest enhanced dopamine release in the striatum, there is evidence for a deficiency of dopamine release in the dorsolateral prefrontal cortex of schizophrenic patients (Slifstein et al., 2015) . The concept of cortical hypodopaminergia in schizophrenia (Weinberger, 1987; Weinberger et al., 1988; Abi-Dargham, 2003) has emerged from converging lines of evidence showing that working memory is deficient in schizophrenia and that optimal prefrontal D1 receptor activation appears to be critical for intact working memory in non-human primates (Goldman-Rakic et al., 2000; Arnsten, 2013) . In addition, it should be noted that current antipsychotics increase dopamine release by blocking D2 autoreceptors on dopaminergic neurons (Boyar and Altar, 1987) , which will indirectly increase postsynaptic D1 tone. It is possible that this increase in D1 tone could contribute to the therapeutic efficacy of D2 antagonists. In light of the above considerations, behavioral and neurochemical data for DETQ presented in this paper support the potential efficacy of D1 potentiators for the treatment of cognitive deficits and negative symptoms in schizophrenia.
Major depressive disorder
Serotonin reuptake inhibitors exert their antidepressant effects with a delay of several weeks (Briley and Moret, 1993) , suggesting a highly indirect mechanism of action. In contrast, dopamine is a direct driver of limbic reward systems, and dopamine-releasing drugs can have immediate mood-elevating effects. These considerations suggest that a D1 potentiator could have a rapid onset of action in its effects on reward systems, and it is possible that the more direct mode of action could translate into greater antidepressant efficacy compared to current standard of care. The high rate of depression in Parkinson's patients (Poewe, 2008) and the increased incidence of depression and suicidal ideation in patients treated with the D1 antagonist SCH39166 (ecopipam) (Astrup et al., 2007) also support a role of dopamine and the D1 receptor in maintaining mood.
In the current study, DETQ reduced immobility in the forcedswim test, a model that is responsive to a broad range of clinically validated antidepressant interventions, including those with non-monoaminergic mechanisms such as electroconvulsant therapy and ketamine (Petit-Demouliere et al., 2005; Witkin et al., 2016) . Although the reduced immobility in the forced-swim test could be related to motor stimulation by DETQ, it should be noted that many CNS stimulants have mood-elevating effects, suggesting that activity of DETQ in the forced-swim test may nevertheless be a predictor of antidepressant efficacy. The ability of DETQ to induce phosphorylation of GluR1 and CREB provides additional support for the possibility that D1 potentiators may have utility in major depressive disorder (Svenningsson et al., 2007) . In summary, the current results with DETQ in the forced-swim test and in GluR1/ CREB phosphorylation reinforce expectations from the clinical literature that amplification of the D1 signaling system may have a beneficial effect in major depressive disorder.
Other applications
Dopamine-releasing agents are used as vigilance enhancers (treating narcolepsy and excessive daytime sleepiness) and for attention deficit hyperactivity disorder (Iversen and Iversen, 2007) . The ability of DETQ to cause wakefulness in the sleep EEG model and its activity in enhancing ACh and histamine release supports utility in these two indications. The inhibition of spontaneous alternation in the Y-maze by amphetamines (Anisman and Kokkinidis, 1975) and D1 agonists (this study) suggests that the actions of these agents may produce a blend of pro-and anticognitive effects. Given that DETQ did not inhibit spontaneous alternation, it may possess advantages over other dopaminergic agents in its overall effects on cognition.
Conclusions
Previously reported preclinical and clinical studies have indicated the potential utility of D1 agonists for the treatment of neuropsychiatric disorders; however, limitations of these agents have so far prevented any selective D1 agonist from being approved as therapy. D1 potentiators, by amplifying the effects of endogenous dopamine when and where it is released, offer a new, more physiological approach to D1 receptor activation. The CNS pharmacology of the novel D1 potentiator DETQ aligns closely with that of D1 agonists, but with important differences. For instance, DETQ does not induce stereotypy or desensitization (Svensson et al., 2017) , and it does not inhibit spontaneous alternation in the Ymaze. The behavioral and neurochemical results reported with DETQ in the current study suggest efficacy in Parkinson's disease and other neuropsychiatric disorders. Accordingly, we believe these data support the study of D1 potentiators for the treatment of a broad range of neuropsychiatric disorders. 
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